ℹ️
🇬🇧
Search
Search for people relevant for "různé"
různé
Person
Class
Person
Publication
Programmes
prof. PharmDr. Tomáš Šimůnek Ph.D.
Academic staff at Faculty of Pharmacy in Hradec Králové
15 classes
162 publications
Classes
class
Molecular Biology
+6
GAF144 |
Faculty of Pharmacy in Hradec Králové
class
Molecular Biology and Genetics
+5
GAF370 |
Faculty of Pharmacy in Hradec Králové
class
Molecular Basis of Pharmacology and Toxicology
+1
GDEFX05 |
Faculty of Pharmacy in Hradec Králové
Load more classes (5)
Publications
publication
Hydrophobicity-enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells
2023 |
Faculty of Pharmacy in Hradec Králové
publication
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up
2022 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine
2022 |
Faculty of Pharmacy in Hradec Králové
publication
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions
2021 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo
2021 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation
2021 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
2021 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
2020 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline
2019 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study
2019 |
Faculty of Pharmacy in Hradec Králové
Load more publications (152)
Loading network view...